Clinical Trials Logo

Atrium; Fibrillation clinical trials

View clinical trials related to Atrium; Fibrillation.

Filter by:

NCT ID: NCT06402851 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE (VISIONAIRE)

VISIONAIRE
Start date: July 2024
Phase: Phase 4
Study type: Interventional

VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including 1500 patients with atrial fibrillation or atrial flutter and advanced chronic kidney disease

NCT ID: NCT06165510 Not yet recruiting - Clinical trials for Persistent Atrial Fibrillation

Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation

CLIP-AF
Start date: January 2024
Phase: N/A
Study type: Interventional

A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).

NCT ID: NCT05973474 Not yet recruiting - Clinical trials for Cardiovascular Diseases

The Atherogenic Index of Plasma(AIP) in Patients With Atrial Fibrillation

Start date: July 30, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about The Atherogenic Index of Plasma(AIP) in patients with atrial fibrillation(AF). The main questions it aims to answer are: (1)To investigate the correlation between AIP and the occurrence rate of AF. (2) To investigate the correlation between AIP and the occurrence rate of cardiovascular outcome events (MACE events, heart failure, embolism events) in patients with AF. Patients's clinical data including medical history, laboratory tests, and imageological examination will be collected and further analysed.

NCT ID: NCT05633303 Recruiting - Clinical trials for Atrium; Fibrillation

Personalised Ablation Strategies in AF

PAS
Start date: October 14, 2022
Phase: N/A
Study type: Interventional

Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.

NCT ID: NCT05456204 Recruiting - Clinical trials for Atrium; Fibrillation

Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

It is planned to evaluate the efficacy and safety of the class III antiarrhythmic drug refralon as a drug for pharmacological cardioversion in patients with recurrent atrial fibrillation (AF) and atrial flutter (AFL) after catheter ablation.

NCT ID: NCT05434650 Recruiting - Atrial Arrhythmia Clinical Trials

Abbott Atrial Fibrillation Post Approval Study

Start date: October 21, 2022
Phase:
Study type: Observational

This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) for the treatment of AF.

NCT ID: NCT04545437 Recruiting - Stroke Clinical Trials

The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study

C3
Start date: August 10, 2020
Phase:
Study type: Observational

The aim this study will be to find out which patients are at risk of heart attacks/strokes up to several years after discharge from an ICU. This study will also investigate whether treatments and events occurring in ICU contribute to this risk.

NCT ID: NCT04293198 Completed - Ablation Clinical Trials

Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation

PROOF
Start date: November 4, 2020
Phase:
Study type: Observational

Prospective, multi-center, non-randomized, open label, double arm study to assess the performance of the KODEX-EPD PV occlusion viewer. This study includes patients with atrial fibrillation who are scheduled to undergo a cryo balloon ablation procedure for their atrial fibrillation.

NCT ID: NCT03487419 Recruiting - Clinical trials for Atrium; Fibrillation

Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery

Start date: August 1, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of this study to investigate the correlation between preoperative LA function using 2D echocardiography and left atrium 2D speckle tracking strain echocardiography and the development of Post Operative AF after CABG. the investigators chose electrocardiography as a reference standard for detection of Post Operative AF. LA dysfunction is diagnosed with Echocardiography

NCT ID: NCT03477734 Completed - Clinical trials for Atrium; Fibrillation

Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation

Start date: February 20, 2019
Phase: N/A
Study type: Interventional

A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation. The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib) based on a comparison to a control device, which is an off-the-shelf cleared Holter ECG device